Circassia Pharmaceuticals (NIOX) Price & Analysis

Compare

13 Followers

NIOX Stock Chart & Stats

Day’s Range― - ―

52-Week Range53.40p - 80.00p

Previous CloseN/A

Volume260.54K

Average Volume (3M)838.80K

Market Cap

£305.85M

Enterprise Value235.23M

Total Cash (Recent Filing)£10.90M

Total Debt (Recent Filing)£1.50M

Price to Earnings (P/E)83.2

Beta1.10

Next Earnings

Mar 24, 2026

EPS EstimateN/A

Last Dividend Ex-Date

May 15, 2025

Dividend Yield3.07%

Share Statistics

EPS (TTM)N/A

Shares Outstanding417,826,170

10 Day Avg. Volume1,058,085

30 Day Avg. Volume838,796

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

£76.00

Price Target Upside3.83% Upside

Rating ConsensusHold

Number of Analyst Covering1

Bulls Say, Bears Say

Bulls Say

Acquisition InterestNIOX has announced it has received a possible 81p/share all-cash offer from Keensight Capital valuing the business at £322m.

Market CompetitionThere also appear to be other counterparties considering an offer for the business so competing bids may yet emerge.

Shareholder ValueThe offer represents good value for shareholders for a single-product business in this space.

Bears Say

Acquisition UncertaintyDiscussions are early stages with no formal offer as yet from Keensight.

Macroeconomic EnvironmentKeensight Capital has announced that it does not intend to make a firm offer for the business at this stage due to the current uncertain macroeconomic environment.

Share Price VolatilityA level of weakness in the share price is anticipated due to recent newsflow and share price action related to it.

Circassia Pharmaceuticals News

NIOX Group Updates Total Voting Rights After Share Option Exercise

Circassia Pharmaceuticals ( ($GB:NIOX) ) just unveiled an announcement. NIOX Group plc, a company listed on the AIM...

25d ago

NIOX Group Updates Total Voting Rights Following Employee Share Option Exercise

Circassia Pharmaceuticals ( ($GB:NIOX) ) has shared an update. NIOX Group plc, a company listed on the AIM...

2M ago

NIOX Group CEO’s Associate Increases Shareholding

The latest announcement is out from Circassia Pharmaceuticals ( ($GB:NIOX) ). NIOX Group plc, a company listed on...

2M ago

NIOX Group Reports Strong H1 2025 Performance Amid Strategic Focus

Circassia Pharmaceuticals ( ($GB:NIOX) ) just unveiled an announcement. NIOX Group plc reported a robust performance for the...

3M ago

NIOX Group Issues New Shares to Non-Executive Chairman

Circassia Pharmaceuticals ( ($GB:NIOX) ) has shared an update. NIOX Group plc, a company listed on AIM, has...

3M ago

Rathbones Increases Stake in Niox Group PLC

Circassia Pharmaceuticals ( ($GB:NIOX) ) has issued an announcement. Niox Group PLC, a UK-based issuer, has experienced a...

3M ago

Niox Group PLC Shareholder Update: Rathbones Adjusts Voting Rights

Circassia Pharmaceuticals ( ($GB:NIOX) ) has shared an announcement. Niox Group PLC, a UK-based company, has announced a...

3M ago

NIOX Group Announces Change in Voting Rights

Circassia Pharmaceuticals ( ($GB:NIOX) ) has shared an update. NIOX Group PLC, a company involved in the pharmaceutical...

3M ago

NIOX Group Updates Total Voting Rights Following Share Option Exercises

Circassia Pharmaceuticals ( ($GB:NIOX) ) has shared an announcement. NIOX Group plc, a company listed on AIM, has...

4M ago

Niox Group PLC Announces Change in Voting Rights

Circassia Pharmaceuticals ( ($GB:NIOX) ) has shared an update. Niox Group PLC, a UK-based company, has undergone a...

4M ago

Niox Group upgraded to Buy from Hold at Panmure Liberum

Panmure Liberum upgraded Niox Group (CSSPF) to Buy from Hold with a 69 GBp price target Published first...

8M ago

Circassia Group initiated with a Hold at Deutsche Bank

Deutsche Bank initiated coverage of Circassia Group with a Hold rating and 250 GBp price target. The analyst...

1y ago

NIOX FAQ

What was Circassia Pharmaceuticals’s price range in the past 12 months?

Circassia Pharmaceuticals lowest share price was 53.40p and its highest was 80.00p in the past 12 months.

What is Circassia Pharmaceuticals’s market cap?

Circassia Pharmaceuticals’s market cap is £305.85M.

When is Circassia Pharmaceuticals’s upcoming earnings report date?

Circassia Pharmaceuticals’s upcoming earnings report date is Mar 24, 2026 which is in 179 days.

How were Circassia Pharmaceuticals’s earnings last quarter?

Currently, no data Available

Is Circassia Pharmaceuticals overvalued?

According to Wall Street analysts Circassia Pharmaceuticals’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Circassia Pharmaceuticals pay dividends?

Circassia Pharmaceuticals pays a Annually dividend of 1.25p which represents an annual dividend yield of 3.07%. See more information on Circassia Pharmaceuticals dividends here

What is Circassia Pharmaceuticals’s EPS estimate?

Circassia Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Circassia Pharmaceuticals have?

Circassia Pharmaceuticals has 417,826,170 shares outstanding.

What happened to Circassia Pharmaceuticals’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Circassia Pharmaceuticals?

Currently, no hedge funds are holding shares in GB:NIOX

Circassia Pharmaceuticals Stock Smart Score

Neutral

Fundamentals

Return on Equity

4.55%

Trailing 12-Months

Asset Growth

-25.25%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Circassia Pharmaceuticals

NIOX Group Plc engages in the design, development, and commercialization of medical devices for the measurement of fractional exhaled nitric oxide (FeNo) worldwide. Its products include NIOX VERO, a non-invasive and point-of-care system that comprises a small portable device and a range of consumables, including sensors, individual disposable mouthpieces, and breathing handles for the measurement of FeNo level in patients. The company was formerly known as Circassia Group Plc and changed its name to NIOX Group Plc in September 2022. NIOX Group Plc was incorporated in 2006 and is headquartered in Oxford, the United Kingdom.

Circassia Pharmaceuticals (NIOX) Earnings & Revenues

Historic Earnings Reports

NIOX Stock 12 Month Forecast

Average Price Target

76.00p

▲(3.83% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"30":"30p","77":"77p","41.75":"41.8p","53.5":"53.5p","65.25":"65.3p"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":76,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">76.00p</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":76,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">76.00p</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":76,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">76.00p</span>\n  </div></div>","useHTML":true}}],"tickPositions":[30,41.75,53.5,65.25,77],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2024","6":"Jan<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,70,70.46153846153847,70.92307692307692,71.38461538461539,71.84615384615384,72.3076923076923,72.76923076923077,73.23076923076923,73.6923076923077,74.15384615384616,74.61538461538461,75.07692307692308,75.53846153846153,{"y":76,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,70,70.46153846153847,70.92307692307692,71.38461538461539,71.84615384615384,72.3076923076923,72.76923076923077,73.23076923076923,73.6923076923077,74.15384615384616,74.61538461538461,75.07692307692308,75.53846153846153,{"y":76,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,70,70.46153846153847,70.92307692307692,71.38461538461539,71.84615384615384,72.3076923076923,72.76923076923077,73.23076923076923,73.6923076923077,74.15384615384616,74.61538461538461,75.07692307692308,75.53846153846153,{"y":76,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":33.22,"date":1538352000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":31.26,"date":1656633600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":66.45,"date":1693526400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68.19,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":67.77,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":67.38,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":61.88,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":61.68,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":74.05,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":63.84,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68.2,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":70,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >